SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients

Summary

The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by EGFR mutation, gender, smoking history, and type of tumor.

Timeline

Start

2007-01

Primary completion

2009-01

Completion

2009-01

Drugs

Indications